Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Dig Liver Dis. 2019 Feb 3;51(9):1330–1336. doi: 10.1016/j.dld.2019.01.017

Figure 1. Distribution of liver fibrosis scores’ risk classes across categories of frailty and sarcopenia.

Figure 1.

(p values are for chi-squared test; post-hoc chi-squared comparison with Bonferroni correction was performed to verify the statistical significance of the reduced prevalence of sarcopenia in BARD high compared to intermediate risk class: p=0.48)